As per the terms of the agreement, AstraZeneca has licensed Galderma Pharma to access a number of compounds from its portfolio for the development of new treatments for dermatological indications.
Initially, the companies will target diseases related to oncology, inflammation and central nervous system.
The financial terms of the five-year agreement were not disclosed.
AstraZeneca New Opportunities Innovative Medicines Unit head Clive Morris said partnering with Galderma is the most efficient and effective way to unlock the potential of the compounds in this rapidly evolving disease area.